AREVA Med

decorative

About AREVA Med

AREVA Med is an AREVA subsidiary created in 2009 to develop innovative therapies to fight cancer.

decorative

Nuclear Medicine

Learn more about nuclear medicine and targeted alpha therapy (TAT) with lead-212, and about our ongoing research.

decorative

Clinical Trials

The first Phase 1 clinical trial of lead-212 is currently taking place in the United States.

decorative

News & Materials

Read about the latest news and events, watch a video, or download our brochure.

decorative

Macrocyclics

Macrocyclics, an AREVA Med company, is the global leader in chelating agent technologies for medicine.

Latest News

AREVA Med to expand production capacities in the U.S.

11/03/2014

AREVA Med to expand production capacities in the U.S.

Read more
Macrocyclics introduces new offices in Asia and Europe

07/07/2014

Macrocyclics introduces new offices in Asia and Europe

Read more
AREVA Med selects Caen for its future lead-212 production facility

02/12/2014

AREVA Med selects Caen for its future lead-212 production facility

Read more
Contact

For more information about AREVA Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673

Contact

For more information about Macrocyclics, please contact:

Garry Kiefer

Tel.: + 1 (972) 250-2248

Linked In
decorative

Follow AREVA Med on

Twitter
decorative

Follow @AREVAmed on